Royal Children's Hospital Research Foundation

Antisense Therapeutics Limited

Otolanum Ag

Murdock Children's Research Institute

Christopher John Wraight

Kenneth W Dobie

Nicholas M Dean

George Arthur Werther

George Tachas

Thomas Meyer

Lynne Maree Atley

Stephanie Ruth Edmondson

The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal application.

Pharmaceutical composition comprising betahistine

Provided herein are methods, compounds, and compositions for reducing expression of an IGF-IR mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions that inhibit expression of IGF-IR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate the tumor or cancer, or a symptom thereof.

Modulation of insulin like growth factor I receptor expression in cancer

The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflamatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a most preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis.

Method for the prophylaxis and/or treatment of medical disorders

The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a most preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis.

Method for the prophylaxis and/or treatment of proliferative and /or inflammatory skin disorders

Method for the prophylaxis and/or treatment of proliferative and/or

Growing community of inventors

Blackburn, Australia

Christopher John Wraight